SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates Against Symptomatic Infection

Amy J. Schuh; Panayampalli S. Satheshkumar; Stephanie Dietz; Lara Bull-Otterson; Myrna Charles; Chris Edens; Jefferson M. Jones; Kristina L. Bajema; Kristie E.N. Clarke; L. Clifford McDonald; Sadhna Patel; Kendra Cuffe; Natalie J. Thornburg; Jarad Schiffer; Kelly Chun; Monique Bastidas; Manory Fernando; Christos J. Petropoulos; Terri Wrin; Suqin Cai; Dot Adcock; Deborah Sesok-Pizzini; Stanley Letovsky; Alicia M. Fry; Aron J. Hall; Adi V. Gundlapalli.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21266812

Documentos relacionados

  1. SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic Infection.
  2. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
  3. Antibody Avidity Maturation Following Recovery From Infection or the Booster Vaccination Grants Breadth of SARS-CoV-2 Neutralizing Capacity.
  4. Adaptive immune responses to SARS-CoV-2 persist in the pharyngeal lymphoid tissue of children.
  5. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization.
  6. Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants.
  7. Innate Immunity in Protection and Pathogenesis During Coronavirus Infections and COVID-19.
  8. Estimated protection against COVID-19 based on predicted neutralisation titres from multiple antibody measurements in a longitudinal cohort, France, April 2020 to November 2021.
  9. Deep mutational scanning identifies SARS-CoV-2 Nucleocapsid escape mutations of currently available rapid antigen tests.
  10. T cell responses to SARS-CoV-2 spike cross-recognize Omicron.